scholarly journals Quantitative consequences of protein carriers in immunopeptidomics and tyrosine phosphorylation MS2 analyses

2021 ◽  
pp. 100104
Author(s):  
Lauren E. Stopfer ◽  
Jason E. Conage-Pough ◽  
Forest M. White
2021 ◽  
Author(s):  
Lauren Elizabeth Stopfer ◽  
Jason E Conage-Pough ◽  
Forest White

Utilizing a protein carrier in combination with isobaric labeling to "boost" the signal of other low-level samples in multiplexed analyses has emerged as an attractive strategy to enhance data quantity while minimizing protein input in mass spectrometry analyses. Recent applications of this approach include pMHC profiling and tyrosine phosphoproteomics, two applications that are often limited by large sample requirements. While including a protein carrier has been shown to increase the number of identifiable peptides in both applications, the impact of a protein carrier on quantitative accuracy remains to be thoroughly explored, particularly in relevant biological contexts where samples exhibit dynamic changes in abundance across peptides. Here, we describe two sets of analyses comparing MS2-based quantitation using a 20x protein carrier in pMHC analyses and a high (~100x) and low (~9x) protein carrier in pTyr analyses, using CDK4/6 inhibitors and EGF stimulation to drive dynamic changes in the immunopeptidome and phosphoproteome, respectively. In both applications, inclusion of a protein carrier resulted in an increased number of MHC peptide or phosphopeptide identifications, as expected. At the same time, quantitative accuracy was adversely affected by the presence of the protein carrier, altering interpretation of the underlying biological response to perturbation. Moreover, for tyrosine phosphoproteomics, the presence of high levels of protein carrier led to a large number of missing values for endogenous phosphopeptides, leading to fewer quantifiable peptides relative to the control condition. These data highlight the unique limitations and future experimental considerations for both analysis types and provide a framework for assessing quantitative accuracy in protein carrier experiments moving forward.


2001 ◽  
Vol 120 (5) ◽  
pp. A168-A168
Author(s):  
T KAIHARA ◽  
T KUSAKA ◽  
H KAWAMATA ◽  
Y ODA ◽  
J IMURA ◽  
...  

1994 ◽  
Vol 72 (06) ◽  
pp. 937-941 ◽  
Author(s):  
Karim Rezaul ◽  
Shigeru Yanagi ◽  
Kiyonao Sada ◽  
Takanobu Taniguchi ◽  
Hirohei Yamamura

SummaryIt has been demonstrated that activation of platelets by platelet-activating factor (PAF) results in a dramatic increase in tyrosine phosphorylation of several cellular proteins. We report here that p72 syk is a potential candidate for the protein-tyrosine phosphorylation following PAF stimulation in porcine platelets. Immunoprecipitation kinase assay revealed that PAF stimulation resulted in a rapid activation of p72 syk which peaked at 10 s. The level of activation was found to be dose dependent and could be completely inhibited by the PAF receptor antagonist, CV3988. Phosphorylation at the tyrosine residues of p72 syk coincided with activation of yllsyk. Pretreatment of platelets with aspirin and apyrase did not affect PAF induced activation of p72 syk .Furthermore, genistein, a potent protein-tyrosine-kinase inhibitor, diminished PAF-induced p72 syk activation and Ca2+ mobilization as well as platelet aggregation. These results suggest that p72 syk may play a critical role in PAF-induced aggregation, possibly through regulation of Ca2+ mobilization.


2018 ◽  
Author(s):  
Daniel D. Brauer ◽  
Emily C. Hartman ◽  
Daniel L.V. Bader ◽  
Zoe N. Merz ◽  
Danielle Tullman-Ercek ◽  
...  

<div> <p>Site-specific protein modification is a widely-used strategy to attach drugs, imaging agents, or other useful small molecules to protein carriers. N-terminal modification is particularly useful as a high-yielding, site-selective modification strategy that can be compatible with a wide array of proteins. However, this modification strategy is incompatible with proteins with buried or sterically-hindered N termini, such as virus-like particles like the well-studied MS2 bacteriophage coat protein. To assess VLPs with improved compatibility with these techniques, we generated a targeted library based on the MS2-derived protein cage with N-terminal proline residues followed by three variable positions. We subjected the library to assembly, heat, and chemical selections, and we identified variants that were modified in high yield with no reduction in thermostability. Positive charge adjacent to the native N terminus is surprisingly beneficial for successful extension, and over 50% of the highest performing variants contained positive charge at this position. Taken together, these studies described nonintuitive design rules governing N-terminal extensions and identified successful extensions with high modification potential.</p> </div>


2015 ◽  
Vol 20 (1) ◽  
pp. 65-78
Author(s):  
Manuel Ramos-Kuri ◽  
Enrique Salgado-Sánchez

Se revisan los avances recientes en el síndrome de Down (SD), haciendo énfasis en su terapia molecular y potencial terapéutico en enfermedades como Alzheimer (EA) y otros trastornos de déficit cognoscitivo. El SD es la principal causa de retraso mental a nivel mundial, causado por la trisomía completa o parcial del cromosoma 21, y es bien conocida su estrecha relación con la EA, de inicio muy temprano. La sobre-expresión de genes del cromosoma 21 es la principal causa del SD, pero se han identificado algunos genes especialmente importantes. Por ejemplo, el gen DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase) participa en el déficit cognitivo tanto en SD como en la EA. Su fisiopatología es porque el exceso de DYRK1A hiper fosforila a la proteína precursora de amiliode (APP) y a la unidad asociada a tubulina (TAU) proteínas bien conocidas en la génesis de la EA. Otra aplicación potencial es que los pacientes con SD presentan menor incidencia de tumores sólidos; su mecanismo es inhibiendo angiogénesis, por inhibición del factor de crecimiento vascular endotelial (VEGF) a través de la inhibición de calcineurina, gracias a la sobre-expresión del gen DSCR-1 presente en el cromosoma 21. Aunque el SD aún no cuenta con terapia específica, se realiza terapia molecular en modelos murinos con SD, con dos péptidos intestinales vasoactivos NAP y SAL. Los ratones así tratados mostraron una clara disminución en el déficit cognoscitivo, sugiriendo un alto potencial terapéutico para el SD; así como, otros tipos de retardo mental y déficit de aprendizaje.


Sign in / Sign up

Export Citation Format

Share Document